Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
|Videos|November 8, 2017
Dr. Haldorsen on the Role of Imaging in the Diagnosis of Endometrial Cancer
Author(s)Ingfrid Haldorsen, MD
Ingfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, discusses the role of imaging in the diagnosis of endometrial cancer.
Advertisement
Ingfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, discusses the role of imaging in the diagnosis of endometrial cancer.
Preoperative imaging is an important part of the primary diagnostic work-up. It guides the choice of surgical procedure, and adjuvant therapy, says Haldorsen.
In recent years, there has been a dramatic advancement in the development of novel functional imaging techniques that enables depiction of microstructural and microvascular features of the tissue, Haldorsen adds.
Advertisement
Related to this article
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
First-line pembrolizumab monotherapy met the primary end point of PFS in dMMR advanced/recurrent endometrial cancer.
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
NMPA Accepts Toripalimab Plus Chemotherapy Application for Expanded Stage II-III NSCLC Use
3
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
4
Dr Hoffmann on the Significance of Efficacy Data for Sonrotoclax Plus Zanubrutinib in MCL
5